60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) and Antibe Therapeutics (OTCMKTS:ATBPF – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.
Insider & Institutional Ownership
8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 10.3% of 60 Degrees Pharmaceuticals shares are held by company insiders. Comparatively, 9.0% of Antibe Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares 60 Degrees Pharmaceuticals and Antibe Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 60 Degrees Pharmaceuticals | N/A | N/A | -86.34% |
| Antibe Therapeutics | N/A | -56.48% | -29.07% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 60 Degrees Pharmaceuticals | 0 | 1 | 1 | 0 | 2.50 |
| Antibe Therapeutics | 0 | 1 | 0 | 0 | 2.00 |
60 Degrees Pharmaceuticals presently has a consensus target price of $2.40, suggesting a potential upside of 53.85%. Given 60 Degrees Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Antibe Therapeutics.
Valuation & Earnings
This table compares 60 Degrees Pharmaceuticals and Antibe Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 60 Degrees Pharmaceuticals | $352,864.00 | 53.96 | -$3.77 million | ($1.04) | -1.50 |
| Antibe Therapeutics | N/A | N/A | -$14.73 million | ($0.25) | -0.86 |
60 Degrees Pharmaceuticals has higher revenue and earnings than Antibe Therapeutics. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
60 Degrees Pharmaceuticals beats Antibe Therapeutics on 8 of the 11 factors compared between the two stocks.
About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
About Antibe Therapeutics
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.
Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
